<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02760017</url>
  </required_header>
  <id_info>
    <org_study_id>401336/2013-1</org_study_id>
    <nct_id>NCT02760017</nct_id>
  </id_info>
  <brief_title>Bauhinia Forficata in Diabetic Patients</brief_title>
  <official_title>Evaluation of Clinical Efficacy Capsules Containing Standardized Extract of Bauhinia Forficata (Pata- De-vaca) in Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Conselho Nacional de Desenvolvimento Científico e Tecnológico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Among the plants most used in folk medicine for the treatment of diabetes are the species of
      the genus Bauhinia (Fabaceae), popularly known in Brazil as &quot;pata-de-vaca&quot;. Of these,
      Bauhinia forficata has the highest number of studies regarding the hypoglycemic activity. Due
      to this fact it is included in the Medicinal Plants List of the Brazilian Public Health
      System. Extracts of pata-de-vaca (B. forficata) have been explored both in relation to its
      chemical composition and its pharmacological potential. From the chemical point of view the
      main components identified in hydro alcoholic extract of the leaves are O-glycosylated
      derivatives of kaempferol and quercetin. Regarding pharmacological properties preclinical
      studies have confirmed the hypoglycemic effect and antidiabetic of the hydroalcoholic extract
      of the leaves of B. forficata. The search for evidence of the alleged anti-diabetic activity
      of B. forficata in clinical level was performed in only two studies, both with few patients,
      and questionable methodological quality that used tea as a pharmaceutical form, a fact that
      allows us to question the validity of data considering the risks of no dose reproducibility
      ingested by patients during the study. Thus the investigators here intend to determine the
      effects of a standardized extract of B. forficata in the control of patients with diabetes
      mellitus
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>glycated hemoglobin levels</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>fasting glucose levels</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma inflammatory parameters levels</measure>
    <time_frame>4 months</time_frame>
    <description>Interleukin-6 and c-reactive protein levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma oxidative stress parameters levels</measure>
    <time_frame>4 months</time_frame>
    <description>Advanded glycation end-products, protein carbonyl and lipid peroxidation levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma endothelin-1 levels</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>capsules containing placebo for B forticata</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B. forficata</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>capsules of B. forficata containing 200 mg of plant extracts</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>B. forficata</intervention_name>
    <arm_group_label>B. forficata</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type II diabetic patients

          -  Using oral antidiabetic treatment for at least 3 months

          -  Glycated hemoglobin levels &gt; 7.5% or

          -  Fasting glucose levels &gt;=100mg/dl

        Exclusion Criteria:

          -  Type 1 diabetes patients

          -  History of cancer under treatment

          -  Major cardiovascular event during the last 90 days (eg. stroke, myocardial infarction)

          -  Pregnancy

          -  Lactation

          -  Serious diseases presenting limited short-term prognosis (eg stage IV COPD end-stage
             heart failure)

          -  Child B or C cirrhotic patients

          -  Patients with chronic renal failure on dialysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Universidade do Extremo Sul Catarinense</name>
      <address>
        <city>Criciuma</city>
        <state>Santa Catarina</state>
        <zip>88801450</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Indianara Reynaud, PharmD</last_name>
      <phone>+55 48 34312571</phone>
      <email>dirunasau@unesc.net</email>
    </contact>
    <investigator>
      <last_name>FELIPE DAL PIZZOL, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2016</study_first_submitted>
  <study_first_submitted_qc>April 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2016</study_first_posted>
  <last_update_submitted>May 24, 2017</last_update_submitted>
  <last_update_submitted_qc>May 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude</investigator_affiliation>
    <investigator_full_name>Felipe Dal Pizzol</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

